Successful Treatment of an Aggressive Tracheal Malignancy With Immunotherapy Asishana A. Osho, MD, MPH, Christopher J. Azzoli, MD, Sara Pai, MD, PhD, Mari Mino-Kenudson, MD, William C. Faquin, MD, PhD, Tiffany G. Huynh, MD, Michael Lanuti, MD, Douglas J. Mathisen, MD, Ashok Muniappan, MD The Annals of Thoracic Surgery Volume 103, Issue 2, Pages e123-e125 (February 2017) DOI: 10.1016/j.athoracsur.2016.08.021 Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions
Fig 1 Tracheal squamous cell carcinoma (A) before and (B) after 9 months of immunotherapy with nivolumab. Note improvement of tracheal luminal patency and overall decrease in size of mass. The Annals of Thoracic Surgery 2017 103, e123-e125DOI: (10.1016/j.athoracsur.2016.08.021) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions
Fig 2 Bronchoscopic images of tracheal tumor. (A) Before core was out on April 16, 2013 at time of presentation for acute respiratory compromise. (B) Seven months after initiation of immunotherapy on surveillance bronchoscopy (November 6, 2015). The Annals of Thoracic Surgery 2017 103, e123-e125DOI: (10.1016/j.athoracsur.2016.08.021) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions
Fig 3 (A) Squamous cell carcinoma infiltrating desmoplastic stroma exhibits strong membrane immunoreactivity for programmed death ligand-1 (PD-L1) (×100, staining performed with 5H1 mononuclear antibody [mAb]). (B) High-magnification view showing well-differentiated squamous cell carcinoma with strong diffuse epithelial membrane immunoreactivity for PD-L1 (×400, staining performed with 5H1 mAb). The Annals of Thoracic Surgery 2017 103, e123-e125DOI: (10.1016/j.athoracsur.2016.08.021) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions